CHI-E7p

CHI-E7p is a chimeric protein-based therapeutic vaccine candidate designed for the treatment of high-risk human papillomavirus (HR-HPV) infections and associated cancers, particularly those caused by HPV16. The construct utilizes the hepatitis B small surface antigen (HBsAg(S)) as a scaffold that self-assembles into nanoparticles. This scaffold is flanked at the N-terminus by the chemokine CCL19 (MIP-3β) and at the C-terminus by interleukin-2 (IL-2) and an artificial HPV16 E7 polytope. The inclusion of CCL19 and IL-2 serves to recruit and activate immune cells, acting as molecular adjuvants to enhance the T-cell response against the E7 oncoprotein without the need for external adjuvants. Preclinical studies in HLA-A2 transgenic mice have demonstrated that CHI-E7p can induce specific T-cell responses and provide protection against tumors expressing HPV16 E6/E7 oncoproteins.

Other names

CCL19-HBsAg-IL2-E7pCCL-19-HBsAg-IL2-E7pCCL 19-HBsAg-IL2-E7p